Pemvidutide is a Synthetic Peptide owned by Altimmune, and is involved in 8 clinical trials, of which 3 were completed, 4 are ongoing, and 1 is planned.
ALT-801 is a highly efficacious agonist at both the GLP-1 and glucagon receptor. It enhances glucose-dependent insulin secretion by the pancreatic beta-cells, suppresses inappropriately elevated glucagon secretion and slows gastric emptying. It binds to and activates the human GLP-1 receptor exhibiting anti-hyperglycemic actions by mechanisms involving cyclic AMP or other intracellular signaling pathways.
The revenue for Pemvidutide is expected to reach a total of $2.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pemvidutide NPV Report.
Pemvidutide (ALT-801) is under development for the treatment of obesity, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and type 2 diabetes. The drug candidate is administered subcutaneously. It is a synthetic peptide and is an analogue of oxyntomodulin. The drug candidate targets GLP-1 and glucagon receptor. It is developed based on EuPort technology.
Altimmune, is a a biopharmaceutical company. It focuses on developing liver disease and immune modulating therapies. The company’s pipeline products include ALT-801, a glucagon receptor to treat metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). Altimmune also offers nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy to patients chronically infected with the hepatitis B virus; nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores. In addition, its products find its application in the treatment of acute respiratory infections, chronic viral infections, and cancer. Altimmune is headquartered in Gaithersburg, Maryland, the US.
The company reported revenues of (US Dollars) US$4.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 46.1% over FY2020. The operating loss of the company was US$96.9 million in FY2021, compared to an operating loss of US$54.8 million in FY2020. The net loss of the company was US$97.1 million in FY2021, compared to a net loss of US$49 million in FY2020.
Quick View – Pemvidutide
|Highest Development Stage|